Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7927617 | 0.67 | CDC25B (0.34) | CDC25ACDC25B | |
| SCHEMBL527160 | 0.67 | ABCG2 (0.46) | ABCG2CDC25ACDC25B | |
| SCHEMBL29470864 | 0.67 | CDC25B (0.34) | CDC25ACDC25B | |
| SCHEMBL1899659 | 0.66 | MAPT (0.37) | CDC25B | |
| SCHEMBL7464999 | 0.64 | ABCG2 (0.55) | ABCG2CDC25ACDC25B | |
| SCHEMBL30019213 | 0.62 | ABCG2 (0.62) | ABCG2 | |
| SCHEMBL261676 | 0.62 | ABCG2 (0.62) | ABCG2 | |
| SCHEMBL29555333 | 0.61 | ABCG2 (0.37) | ABCG2CDC25ACDC25B | |
| SCHEMBL1896809 | 0.60 | GSK3B (0.38) | ABCG2CDC25ACDC25B | |
| SCHEMBL8623122 | 0.59 | CYP2A6 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-20130281523-A1 | LOW DOSE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2013-10-24 | — | — | US | disclosed |
| EP-2640379-A2 | LOW DOSE CANNABINOID MEDICAMENTS | Pier Pharmaceuticals (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20120231083-A1 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012068516-A2 | LOW DOSE CANNABINOID MEDICAMENTS | PIER PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-8178496-B2 | Photoreactive regulator of glutamate receptor function and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011063164-A2 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | STEADY SLEEP RX CO., INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090181454-A1 | PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF | ENERGY, UNITED STATE DEPARTMENT OF | 2009-07-16 | — | — | US | disclosed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | disclosed |
| EP-1427404-A2 | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS | Nedergaard, Maiken (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030050224-A1 | Blocking glutamate function at an ionotropic glutamate receptor. e.g., N-methyl-D-aspartate receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptor and the kainate receptor; brain disorders; spinal chord | NEDERGAARD MAIKEN (US) | 2003-03-13 | — | — | US | disclosed |
| WO-2003015713-A2 | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS | NEDERGAARD MAIKEN (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | disclosed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181454-A1 | PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF | GRM2, GRM1, GRM3 | ABCG2 4327/4885CDC25A 3777/4885CDC25B 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.